Schedule

Wednesday, Nov. 10, 2021

Pre-Conference Programs

no_symbol.png Indicates that the presentation is not available on-demand.
Click
(View On-demand) to view or purchase presentations that are available on-demand.

World Immunotherapy Council's 4th Young Investigator Symposium

Liberty Ballroom (Marriott Marquis)
7:30 a.m.–1 p.m. EST*

7:30 a.m.

Opening Statement 
Organizer

7:45 a.m.

no_symbol.png

Synergistic antitumor activity of pan-PI3K inhibition and immune checkpoint blockade in bladder cancer
Zheng Zhu—Chinese American Hematology Oncology Network (CAHON)

8:02 a.m.

no_symbol.png

Chemokine driven spatially organized tumor immunity fosters long survival
Ziena Abdulrahman, Msc—KWF working society-Dutch Tumor Immunology Meeting (KWF-DTIM)

8:19 a.m.

no_symbol.png

RevCAR platform as a combinatorial approach for targeting acute myeloid leukemia
Liliana Loureiro —Tumor Immunology Meets Oncology (TIMO) 

8:36 a.m.

no_symbol.png

Spontaneous clinical research in immuno-oncology: the reality of the SCITO
Margaret OttavianoSocietà Campana di ImmunoTerapia Oncologica (SCITO) 

8:53 a.m.

no_symbol.png

Hyperprogressive disease in cancer patients: the dark side of immuno-checkpoint blockade. Lessons from clinical practice and preclinical models² 
Roberto Ferrara—Italian Network for Tumor Biotherapy (NIBIT) 

9:10 a.m.

no_symbol.png

Adjuvant and neoadjuvant immunotherapy for hepatocellular carcinoma
Chiun Hsuthe Taiwanese Oncology Society (TOS) 

9:27 a.m.

no_symbol.png

Differential expression of adhesion molecules defines myeloid cell infiltration in  glioblastoma and comprises a therapeutic target
Defne BayikSociety for Immunotherapy of Cancer (SITC) 

9:44 a.m.

no_symbol.png

CRISPR-Cas9-mediated knockout of PD-1 for tumor-infiltrating lymphocyte-based adoptive T-cell therapy
Chris Chamberlain—Scandinavian Network for Immunotherapy of Cancer (SNIC) 

10:01 a.m.

no_symbol.png

Novel model for evaluation of CD3-redirection combinatorial therapies in the context of a syngeneic tumor model with fully competent immune system
Olesya ChornoguzProgress in Vaccination Against Cancer (PIVAC)

10:18 a.m.

no_symbol.png

The clinical utility and safety of Short-course Immune checkpoint inhibitors (ICI) in multiple tumors - A real world multicentric study from India 
George Abraham— Immuno-Oncology Society of India (I-OSI) 

10:35 a.m.

Break

10:45 a.m.

no_symbol.png

JUPITER-06: a randomized, double-blind phase III trial of toripalimab in combination with paclitaxel plus cisplatin for advanced or metastatic ESCC 
Feng Wang— Chinese Society for Clinical Oncology (CSCO) 

11:02 a.m.

no_symbol.png

Trajectory analysis of single cell RNAseq identifies factors involved in immune escape in squamous cell cancers 
Quah Hong Sheng—Singapore Society of Oncology - Cancer Immunotherapy Consortium (SSO-CIC) 

11:19 a.m.

no_symbol.png

Combination of NKT cell immunotherapy and oncolytic vesicular stomatitis virus expressing FAST proteins clears metastatic triple negative breast cancer
Adam Nelson—Canadian Cancer Immunotherapy Consortium (CCIC) 

11:36 a.m.

no_symbol.png

Insights into PD-1 blockade: how the Fc region can modulate the therapeutic activity of monoclonal antibodies targeting PD-1
Julia Moreno-VicenteSpanish Group of Immuno-Biological Therapeutics in Cancer (GETICA) 

11:53 a.m.

no_symbol.png

Evaluation on tumor selectivity of immune response driven by STA551, an anti-CD137 agonist antibody activated in the presence of extracellular ATP
Ryo Uchikawa Japanese Association of Cancer Immunology (JACI) 

12:10 p.m.

no_symbol.png

The effects of short chain fatty acids on the phenotype and function of human dendritic cells matured with Toll like receptor ligands
Katarzyna Piadel  Institute for Cancer Vaccines and Immunotherapy (ICVI) 

12:27 p.m.

no_symbol.png

Identification of genes and pathways associated with immune modulatory properties of biglycan in colorectal cancer cells
Karthikeyan Subbarayan  German Society for Immunology (DGfl

12:45 p.m.

Closing Statement 
Organizer 

The Evolution of Immunotherapy: An Exploration of Immunity Beyond T cells, CAR T in Solid Tumors and Novel Combinations

Independence Ballroom (Marriott Marquis)
2–6 p.m. EST*

Session I: Immunity Beyond T cells
2–3:20 p.m. EST

2 p.m.
Welcome: Unleashing Curiousity, Courage and Conviction for The Next Wave of Immunotherapy
(View On-demand)
Zhen Su, MD, MBA – Marengo Therapeutics

2:10 p.m. Beyond the Horizon. How Targeting Myeloid cells can Revolutionize Cancer Immunotherapy
(View On-demand)
Dmitry I. Gabrilovich, MD, PhD AstraZeneca

2:30 p.m. Leveraging B-cell Immunity to Promote PD-1 blockade Effectiveness in Glioblastoma
(View On-demand)

David Hou – Northwestern University

2:40 p.m.

no_symbol.png

A Combined Strategy of CD70 CAR Co-expression with Membrane-bound IL-15 and CISH Knockout Results in Enhanced NK Cytotoxicity and Persistence
James B. Trager, PhDNkarta Therapeutics

2:50 p.m.

no_symbol.png

Panel Discussion
Moderator:
Francesco M. Marincola, MD – Kite, A Gilead Company
Panelists:
Dmitry I. Gabrilovich, MD, PhD AstraZeneca
David Hou – Northwestern University
Katy Rezvani, MD, PhD – MD Anderson Cancer Center
James B. Trager, PhD Nkarta Therapeutics

   
Session II: CAR T and other Cell Therapies in Solid Tumors
3:204:30 p.m. EST
 

 
3:20 p.m. Equipping CAR T for Solid Tumors: Challenges and Opportunities
(View On-demand)

Carl H. June, MD – University of Pennsylvania


3:40 p.m.

no_symbol.png

Secretion of Matrix Metallopeptidase 8 Promotes Tumor Infiltration and Antitumor Activity of CAR T cells
Irfan N. Bandey, PhD – University of Houston

3:50 p.m. AlloCAR TTM Cells Built for Enhanced Expansion, Persistence, and the Ability to Overcome the Solid Tumor Microenvironment
(View On-demand)

Barbra J. Sasu, PhD – Allogene Therapeutics

4:00 p.m.

no_symbol.png

Debate/Panel Discussion
Moderator: Kald Abdallah, MD, PhD – Bristol Myers Squibb
Panelists: Irfan N. Bandey, PhD – University of Houston
Carl H. June, MD – University of Pennsylvania
Marcela V. Maus, MD, PhD – Massachusetts General Hospital
Barbra J. Sasu, PhD – Allogene Therapeutics

4:30 p.m. Break
   
Session III: Novel Combinations
4:456:00 p.m. EST
 

 
4:45 p.m.

no_symbol.png

The Evolving Landscape of Immunotherapy Combinations
Jonathan Cheng, MD – Bristol Myers Squibb

5:05 p.m. Beyond T cells and Bispecific Antibodies for Solid Tumors: Odyssey of Bispecific Antibody (BiAb) Armed Activated T cells (BATs)
(View On-demand)
Lawrence G. Lum, MD, DSc – University of Virginia

5:15 p.m. INO-5401 and INO-9012 Delivered Intramuscularly (IM) with Electroporation (EP) in Combination with Cemiplimab (REGN2810) in Newly Diagnosed Glioblastoma
(View On-demand)

David A. Reardon, MD – Dana-Farber Cancer Institute

5:25 p.m.

no_symbol.png

Panel Discussion
Moderator: Giovanni Melillo, MD – AstraZeneca
Panelists: Jonathan Cheng, MD – Bristol Myers Squibb
Sandra Demaria, MD – Weill Cornell Medicine
Lawrence G. Lum, MD, DSc – University of Virginia
David A. Reardon, MD – Dana-Farber Cancer Institute
                 
5:55 p.m. Closing Remarks
Kald Abdallah, MD, PhD Bristol Myers Squibb


Thursday, Nov. 11, 2021

Pre-Conference Programs

no_symbol.png Indicates that the presentation is not available on-demand.
Click (View On-demand) to view or purchase presentations that are available on-demand.


Primer on Tumor Immunology and Cancer Immunotherapy™

Liberty Ballroom (Marriott Marquis)
8 a.m.–5:30 p.m. EST

Session I: Generating Anti-Tumor Immunity
8–9:55 a.m. EST
Credits:
.75 CEs Available
8 a.m.
Introduction
(View On-demand)
Yvonne Saenger, MD – Albert Einstein College of Medicine

Credits:
8:05 a.m. 
No CME credits available
The Adaptive Immune Response
(View On-demand)

Jonathan D. Powell, MD, PhD – Calico

8:35 a.m.  Overview of Innate Immunity in Cancer Immunotherapy and Complexities of Macrophages
(View On-demand)

Jennifer L. Guerriero, PhD – Brigham and Women's Hospital

Credits:
9:05 a.m.
No CME credits available
Role of Dendritic Cells in Cancer
(View On-demand)
Niroshana Anandasabapathy, MD, PhD – Weill Cornell Medicine

9:35 a.m. Session I Panel Discussion 
(View On-demand)
Moderator:
Yvonne Saenger, MD – Albert Einstein College of Medicine
Panelists: Session I Speakers

9:55 a.m. Break
   
Session II: Approaches to Immunotherapy I
10:10 a.m.–Noon EST
Credits:
.75 CEs Available
10:10 a.m.
 
Immune Checkpoint Blockade in Cancer Therapy: New Insights into Therapeutic Mechanisms
(View On-demand)
James P. Allison, PhD – The University of Texas MD Anderson Cancer Center

Credits:
10:40 a.m.
No CME credits available
Myeloid Derived Suppressor cells: From the Biology to Therapy
(View On-demand)
Dmitry I. Gabrilovich, MD, PhD – AstraZeneca

Credits:
11:10 a.m.
No CME credits available
Cancer Vaccines
(View On-demand)
Howard L. Kaufman, MD, FACS Amkyra Therapeutics/Massachusetts General Hospital

11:40 a.m. Session II Panel Discussion 
(View On-demand)
Moderator:
Yvonne Saenger, MD – Albert Einstein College of Medicine
Panelists:
Session II Speakers

Noon Lunch

   
Session III: Approaches to Immunotherapy II
1:30–3:25 p.m. EST
 
Credits: 1.75 CEs Available
1:30 p.m.
Introduction
(View On-demand)

Jennifer L. Guerriero, PhD –
Brigham and Women's Hospital

1:35 p.m. Updates on CAR T Cell Therapies
(View On-demand)
Carl H. June, MD – University of Pennsylvania

2:05 p.m. Microbiome
(View On-demand)
Thomas F. Gajewski, MD, PhD – University of Chicago

2:35 p.m. Metabolism in Cancer Immunology and Immunotherapy
(View On-demand)
Greg M. Delgoffe, PhD – University of Pittsburgh

3:05 p.m. Session III Panel Discussion 
(View On-demand)
Moderator:
Jennifer L. Guerriero, PhD – Brigham and Women's Hospital
Panelists:
Session III Speakers

3:25 p.m. Break
   
Session IV: Clinical Practice of Immunotherapy
3:40–5:30 p.m. EST

Credits: 1.75 CEs Available
3:40 p.m. Immune Biomarkers to Guide Clinical Care
(View On-demand)
Yvonne Saenger, MD – Albert Einstein College of Medicine

4:10 p.m. Identification and Management of Immune Related Adverse Events
(View On-demand)
Anna C. Pavlick, MD, MBA – Weill Cornell Medicine

4:40 p.m. What You Need for a Good TIME (Tumor Immune MicroEnvironment)
(View On-demand)

James L. Gulley, MD, PhD, FACP – National Cancer Institute

5:10 p.m. Session IV Panel Discussion 
(View On-demand)
Moderator:
Jennifer L. Guerriero, PhD – Brigham and Women's Hospital
Panelists:
Session IV Speakers

5:25 p.m. Closing Remarks
(View On-demand)
Jennifer L. Guerriero, PhD – Brigham and Women's Hospital


Immuno-Resistance and Sequencing Symposium

Independence Ballroom (Marriott Marquis)
7:30 a.m.–6 p.m. EST


Session I: Novel Primary vs. Adaptive Resistance Mechanisms
7:30–9:15 a.m. EST

7:30 a.m.
Introduction
(View On-demand)
Samir N. Khleif, MD – Georgetown University Medical Center

7:35 a.m.  Anti-PD1 Resistance - Different Flavors
(View On-demand)
Samir N. Khleif, MD – Georgetown University Medical Center

7:55 a.m.  Dissecting the Complexity of HLA Loss in Cancer
(View On-demand)
Christian Hammer, PhD – Genentech, Inc.

8:15 a.m.  Dissecting Evolution of Clinical Immunotherapy Resistance
(View On-demand)
David Liu, MD, MPH, MSDana-Farber Cancer Institute
8:35 a.m. Immune Checkpoint Therapy: Identification of Resistance Mechanisms
(View On-demand)
Padmanee Sharma, MD, PhD – The University of Texas MD Anderson Cancer Center

8:55 a.m. Session I Panel Discussion 
(View On-demand)
Moderator:
Ira Mellman, PhD – Genentech, Inc.
Panelists:
Session I Speakers
Michael B. Atkins, MD – Georgetown Lombardi Comprehensive Cancer        
Center

9:15 a.m. Break
   
Session II: Myths vs. Knowledge on Clinical Therapeutic Mechanisms - Lessons Learned
9:30–11:10 a.m. EST


9:30 a.m. Single Agent Trials, Lessons Learned - OX40 Agonists are Still Alive
(View On-demand)
Andrew D. Weinberg, PhD – Earle A. Chiles Research Institute, Providence Portland Medical Center

9:50 a.m.

no_symbol.png

Role of Tim3 in Myeloid Cells
Vijay K. Kuchroo, DVM, PhD – Center for Neurologic Diseases, BWH

10:10 a.m. Anti-PD1 and IDO1 Inhibition:  Lessons Learned
(View On-demand)

Lance Leopold, MD – Incyte

10:30 a.m. Priming the Immune System to Provoke Checkpoints: The Path to Maintaining the Immunotherapy Momentum
(View On-demand)
Elizabeth M. Jaffee, MD – Sidney Kimmel Cancer Center, Johns Hopkins University

10:50 a.m.

no_symbol.png

Session II Panel Discussion
Moderator:
Andrew D. Weinberg, PhD – Earle A. Chiles Research Institute, Providence Portland Medical Center
Panelists:
Session II Speakers

   
Session III: Understanding the Biology of Therapeutic Pillars - Targeted Pathways and Future Direction
11:10 a.m.–2:20 p.m. EST

11:10 a.m.

no_symbol.png

VISTA Targeting of T cell Quiescence and Myeloid Suppression Overcomes Adaptive Resistance
J. Louise Lines, PhD – Dartmouth College

11:30 a.m. Human Costimulatory Bispecific Antibodies in Cancer Immunotherapy
(View On-demand)

Dimitris Skokos, PhD – Regeneron Pharmaceuticals, Inc.

11:50 a.m. Lunch Break

1:20 p.m. In Pre-clinical Models Metabolic Manipulations Improve the Efficacy of T cell Immunotherapy of Melanoma
(View On-demand)
Hildegund Ertl, MD The Wistar Institute

1:40 p.m.
Molecular Mechanisms of T cell Exhaustion and Relevance for Immunotherapy of Cancer
(View On-demand)
E. John Wherry, PhD – University of Pennsylvania

2:00 p.m.

no_symbol.png

Session III Panel Discussion
Moderator: E. John Wherry, PhD University of Pennsylvania
Panelists:
Session III Speakers

Session IV: Resistance Reversal Strategies & Sequencing
2:20–4:20 p.m. EST

2:20 p.m.

no_symbol.png

Cellular Mechanisms of Cancer Immunity Response and Resistance
Ira Mellman, PhD – Genentech

2:40 p.m.

no_symbol.png

Epigenetic Reprogramming of T cell Differentiation to Enhance Cellular Therapy
Benjamin Youngblood, PhD – St. Jude Children's Research Hospital

3 p.m.

no_symbol.png

Mapping Immunosuppressive Cell in the Tumor Microenvironment
Miriam Merad, MD, PhD – Icahn School of Medicine at Mount Sinai

3:20 p.m. Machine Learning for Spatial Multi-omics in Cancer Immunotherapy
(View On-demand)
Elana Fertig, PhD – Johns Hopkins University

3:40 p.m.

no_symbol.png

Autophagy and Immunometabolism Regulation of CD8+ T cell Antitumor Immunity
Julian J. Lum, PhD – BC Cancer

4 p.m.

no_symbol.png

Panel Discussion – Rational Combination Design
Moderator:
Samir N. Khleif, MD – Georgetown University Medical Center
Panelists:
Session IV Speakers

4:20 p.m. Break
   
Session V: Developmental Process
4:35–6 p.m. EST
 
 
 4:35 p.m. Novel Immunotherapy Clinical Trial Design
(View On-demand)
Osama E. Rahma, MD – AstraZeneca

4:55 p.m. Combinations of Agents without Single-agent Activity
(View On-demand)
Kald Abdallah, MD, PhD – Bristol Myers Squibb

5:15 p.m. Regulatory Considerations for Cancer Immunotherapeutic Development – anti-PD-(L)1 resistance
(View On-demand)
Marc Theoret, MD – Food and Drug Administration (FDA)

5:35 p.m. Panel Discussion
(View On-demand)
Moderator:
Kald Abdallah, MD, PhD – Bristol Myers Squibb
Panelists:
Session V Speakers

5:55 p.m. Closing Remarks
(View On-demand)
Samir N. Khleif, MD – Georgetown University Medical Center


Noon–1:30 p.m. EST

Meet-the-Expert Lunch

6:30–8:30 p.m. EST

Session 1
6:30–7:30 p.m. EST

6:30 p.m.



6:50 p.m.






7:00 p.m.



7:20 p.m.






Session 2
7:30–8:30 p.m. EST

7:30 p.m.



7:45 p.m.








8:15 p.m.

Grant Writing Workshop
Capitol/Congress Room (Marriott Marquis)

Moderator:
Ravi Patel, MD, PhD University of Pittsburgh

Overview of Grant Opportunities
(View On-demand)
Pawel Kalinski, MD, PhD – Roswell Park Comprehensive Cancer Center

Q&A
(View On-demand)
Thomas F. Gajewski, MD, PhD – University of Chicago
Elizabeth Hill, PhD – Medical University of South Carolina

Pawel Kalinski, MD, PhD – Roswell Park Comprehensive Cancer Center
Lillian Kuo, PhD – National Cancer Institute


Principles of Grant Writing
(View On-demand)
Thomas F. Gajewski, MD, PhD – University of Chicago

Q&A
(View On-demand)
Thomas F. Gajewski, MD, PhD – University of Chicago
Elizabeth Hill, PhD – Medical University of South Carolina

Pawel Kalinski, MD, PhD – Roswell Park Comprehensive Cancer Center
Lillian Kuo, PhD – National Cancer Institute



Moderator:
Ravi Patel, MD, PhD University of Pittsburgh

NCI Officer Tips and Tricks
(View On-demand)
Lillian Kuo, PhD National Cancer Institute

Mock Study Section
(View On-demand)
Scientific Review Officer: Lillian Kuo, PhD – National Cancer Institute
Chair: Thomas F. Gajewski, MD, PhD – University of Chicago
Primary Reviewer: Pawel Kalinski, MD, PhD – Roswell Park Comprehensive Cancer Center
Secondary Reviewer: Ravi Patel, MD, PhD – University of Pittsburgh
Statistical Reviewer Elizabeth Hill, PhD – Medical University of South Carolina


Q&A
(View On-demand)
Thomas F. Gajewski, MD, PhD – University of Chicago
Elizabeth Hill, PhD – Medical University of South Carolina

Pawel Kalinski, MD, PhD – Roswell Park Comprehensive Cancer Center
Lillian Kuo, PhD – National Cancer Institute


Friday, Nov. 12, 2021

Annual Meeting
Walter E. Washington Convention Center

7 a.m.–8:30 p.m. EST

no_symbol.png Indicates that the presentation is not available on-demand.
Click (View On-demand) to view or purchase presentations that are available on-demand.

 

 

7 a.m.–8:30 p.m. EST

Poster and Exhibit Hall

Presidential Welcome & Awards Ceremony
Location:
Hall D
Chair:
Patrick Hwu, MD – Moffitt Cancer Center
7:45–8:25 a.m EST

7:45 a.m.

Presidential Welcome
(View On-demand)
Patrick Hwu, MD – Moffitt Cancer Center

7:55 a.m.

Rosenberg Scholar
(View On-demand)

8:05 a.m.

Academy of Immuno-Oncology Awards
(View On-demand)

8:15 a.m.

Team Science Award
(View On-demand)

8:20 a.m.

Lifetime Achievement
(View On-demand)

Session 100: Update Session
Location:
Hall D
Chair:
Patrick Hwu, MD – Moffitt Cancer Center
8:25–8:55 a.m. EST

8:25 a.m.

Food and Drug Administration
(View On-demand)
Adnan Jaigirdar, MD, FACS Food and Drug Administration

8:40 a.m.

Food and Drug Administration
(View On-demand)
Marc Theoret, MD – Food and Drug Administration

8:55–9:05 a.m. EST

Break

Session 101: Keynote Address
Location:
Hall D
Chair:

Patrick Hwu, MD –
Moffitt Cancer Center
9:05–9:55 a.m. EST

9:05 a.m.

Introduction
(View On-demand)
Patrick Hwu, MD – Moffitt Cancer Center

9:10 a.m. 

Neutralizing Protumor Inflammation: Lessons Learned from Preclinical Mouse Models
(View On-demand)
Lisa M. Coussens, PhD – Oregon Health & Science University

9:50 a.m.

Question and Answer
(View On-demand)
Lisa M. Coussens, PhD – Oregon Health & Science University

9:55–10:10 a.m. EST

Break

Session 102: Myeloid Cells
Location:
Hall D
Co-Chairs: 

Niroshana Anandasabapathy, MD, PhD – Weill Cornell Medicine
Miriam Merad, MD, PhD –
Icahn School of Medicine at Mount Sinai
10:10 a.m.–12:10 p.m. EST

10:10 a.m.

Introduction
(View On-demand)
Miriam Merad, MD, PhD – Icahn School of Medicine at Mount Sinai

10:15 a.m.

Myeloid Cells
(View On-demand)
Shannon J. Turley, PhD Genentech

10:35 a.m.

Trem2 in Cancer
(View On-demand)
Marco Colonna, MD – Washington University School of Medicine

10:55 a.m.

Tissue-Resident Macrophages: Fueling Early-Stage Lung Cancer
(View On-demand)
Maria Casanova-Acebes, PhD – Icahn School of Medicine at Mount Sinai

11:15 a.m.

no_symbol.png

CD40
Robert H. Vonderheide, MD, DPhil University of Pennsylvania Perelman School of Medicine

11:35 a.m.

(676) Altered circulating myeloid states associated with anti-PD-1 resistance induce T cell paralysis in human biliary cancer
(View On-demand)
Bridget P. Keenan, MD, PhD University of San Francisco

11:45 a.m.

(209) Genetically Engineered Myeloid Cells (GEMys) as a Platform to Enhance Antitumor Immunity
(View On-demand)
Sabina Kaczanowska, PhD National Cancer Institute

11:55 a.m.

no_symbol.png

(664) Pulmonary priming of tumor-reactive CD8+ T cells by DC1 is impaired by regulatory T cells
Maria Zagorulya, BS – Massachusetts Institute of Technology

12:05 p.m.

Closing Remarks
(View On-demand)
Niroshana Anandasabapathy, MD, PhD – Weill Cornell Medicine

Session 103: Late-Breaking Abstract Sessions
12:10–12:40 p.m. EST
Location:
Hall D
Chair:

Margaret K. Callahan, MD, PhD – Memorial Sloan Kettering Cancer Center

 12:10 p.m.

(951) A Phase 1 first in human study of adenovirally transduced anti-HER2 CAR Macrophages in subjects with HER2 overexpressing solid tumors: preliminary safety, pharmacokinetics, and TME reprogramming data
(View On-demand)

Kim A. Reiss, MD – University of Pennsylvania

12:25 p.m.

(958) BNT211: A phase I/II trial to evaluate safety and efficacy of CLDN6 CAR-T cells and vaccine-mediated in vivo expansion in patients with CLDN6-positive advanced solid tumors
(View On-demand)
Andreas Mackensen, MD – University Hospital of Erlangen

12:40–2:10 p.m. EST

Lunch and Poster Viewing

Concurrent Rapid Oral Abstract Presentation Session 104: Basic Research
Location:
West Salons
Co-Chairs:

Aitziber Buque Martinez, PhD Weill Cornell Medical College
Abigail Overacre-Delgoffe, PhD – University of Pittsburgh

12:55–1:55 p.m. EST

12:55 p.m.

(805) Clonal, activated CD8+ T cells recognizing cardiac alpha-myosin drive immune checkpoint inhibitor associated myocarditis in mice
(View On-demand)

Margaret L. Axelrod, BS Vanderbilt University

1:03 p.m.

(700) Increasing MHC-I expression to potentiate immune checkpoint blockade therapy
(View On-demand)

Shengqing Gu, PhD Dana-Farber Cancer Institute

1:11 p.m.

(310) T cell intrinsic DNA damage and repair response as a novel marker associated with clinical response to PD-1 blockade
(View On-demand)

Yuki Muroyama, MD, PhD University of Pennsylvania Perelman School of Medicine

1:19 p.m.

Question and Answer
(View On-demand)

1:25 p.m.

(693) Mucosal-Associated Invariant T (MAIT) Cell Regulation Networks in Anti-Tumor Immunity
(View On-demand)

Benjamin Ruf, MD National Institutes of Health

1:33 p.m.

(885) Targeting FPR2 as a novel approach for immunotherapy in pancreatic cancer female patients Studies of sexual immune dimorphism in the tumor microenvironment
(View On-demand)

Dhifaf Sarhan, PhD Karolinska Institutet

1:41 p.m.

(651) Molecular signature of neoantigen-reactive CD4+ and CD8+ T cells from metastatic human cancers enables prospective antitumor TCR prediction
(View On-demand)

Frank Lowery III, PhD National Cancer Institute

1:49 p.m.

Question and Answer
(View On-demand)

Concurrent Rapid Oral Abstract Presentation Session 105: Clinical
Location:
East Salons
Co-Chairs:

Allison Betof, MD, PhD – Memorial Sloan Kettering Cancer Center
Rafeh Naqash, MD – Oklahoma University
12:55–1:55 p.m. EST

12:55 p.m.

(457) KEYNOTE-495/KeyImPaCT: interime analysis of a randomized, biomarker-directed, phase 2 trial of pembrolizumab-based combination therapy for non-small cell lung cancer (NSCLC)
(View On-demand)

Martin Gutierrez, MD Hackensack Meridian Health

1:03 p.m.

(300) Longitudinal plasma proteomic profiling of non-small cell lung cancer patients undergoing immune checkpoint blockade-based therapy
(View On-demand)

Michal Harel, PhD Oncohost LTD

1:11 p.m.

(832) Deep learning reveals predictive sequence concepts within immune repertoires to immunotherapy
(View On-demand)

John-William Sidhom, MD, PhD Johns Hopkins University School of Medicine

1:19 p.m.

Question and Answer
(View On-demand)

1:25 p.m.

no_symbol.png

(503) Clinical Activity of ICT01, an anti-BTN3A-Targeting, γ9δ2-Activating mAb, Alone and in Combination with Pembrolizumab in Patients with Advanced/Refractory Solid Tumors: EVICTION Trial
Martin Wermke Uniklinikum Dresden

1:33 p.m.

(379) Immune infiltrates are associated with clinical outcomes in patients with resectable soft tissue sarcoma (STS) treated with neoadjuvant immune checkpoint blockade (ICB)
(View On-demand)

Emily Z. Keung, MD, MA The University of Texas MD Anderson Cancer Center

1:41 p.m.

(354) Lenvatinib and pembrolizumab in advanced endometrial carcinoma (EC): long-term efficacy and safety update from a phase 1b/2 study
(View On-demand)

Vicky Makker, MD Memorial Sloan Kettering Cancer Center

1:49 p.m.

Question and Answer
(View On-demand)

Concurrent Session 106: Exhaustion vs. stem-like TILs – TILs classification
Location:
West Salons
Co-Chairs:

Andrea Schietinger, PhD – Memorial Sloan Kettering Cancer Center
Catherine J. Wu, MD –
Dana-Farber Cancer Institute
2:10–3:25 p.m. EST

2:10 p.m.

no_symbol.png

Biomarkers of Exhaustion Guide the Identification of Tumor-Reactive TIL and Peripheral Blood Lymphocytes
Alena Gros, PhD – Vall d'Hebron Institute of Oncology

2:35 p.m.

Transcriptional Strategies to Counter T Cell
(View On-demand)

Patrick G. Hogan, PhD La Jolla Institute of Immunology

3:00 p.m.

no_symbol.png

(Re)modeling Melanoma Tumor Infiltrating Lymphocytes
Niroshana Anandasabapathy, MD, PHD – Weill Cornell Medicine

Concurrent Session 107: Re-Imagine Patient Access and Care Delivery in the Era of Digital Medicine
Location:
204ABC
Co-Chairs: 

Lynda Chin, MD – Dell Medical School and Apricity Health LLC
Patricia Brown, JD – Medically Home Group
2:10–3:25 p.m. EST

2:10 p.m.

Precision in Care Delivery and Therapeutic Development in the Era of Digital Medicine
(View On-demand)

Sean Khozin, MD, MPH – CancerLinQ

2:15 p.m.

Bio/Pharma Perspective
(View On-demand)
Rasika Kalamegham, PhD – Genentech Roche

2:20 p.m.

Leveraging Digital Platforms to Achieve the Triple Aim
(View On-demand)

Patricia Brown, JD – Medically Home Group

2:25 p.m.

Creating a Learning Health Ecosystem to Connect Real-World Care and Discovery Research
(View On-demand)

Lynda Chin, MD – Dell Medical School and Apricity Health

2:30 p.m.

Panel Discussion
(View On-demand)

Concurrent Session 108: NK Cells
Location:
207
Co-Chairs: 

Lewis L. Lanier, PhD – University of California San Francisco
Katy Rezvani, MD, PhD –
The University of Texas MD Anderson Cancer Center
2:10–3:25 p.m. EST

2:10 p.m.

Introduction
(View On-demand)
Katy Rezvani, MD, PhD – The University of Texas MD Anderson Cancer Center

2:15 p.m.

Natural Killer Cell Diversity and Activation
(View On-demand)
Lewis L. Lanier, PhD – University of California San Francisco

2:30 p.m.

Tumor Infiltrating NK Cells
(View On-demand)
Heidi Cerwenka – University of Heidelberg

2:45 p.m.

Adaptive NK Cells
(View On-demand)
Karl-Johan Malmberg, MD, PhD – Oslo University Hospital

3 p.m.

CRISPR-edited NK Cells
(View On-demand)
May Daher, MD – The University of Texas MD Anderson Cancer Center

3:15 p.m.

(216) Multiplex base editing of NK cell to enhance cancer immunotherapy
(View On-demand)
Minjing Wang, BSc University of Minnesota

Concurrent Session 109: Biomarkers (Early Trials and Translational Research, Tissue Access Aspects)
Location:
Hall D
Co-Chairs:

Sangeeta Goswami, MD, PhD – The University of Texas MD Anderson Cancer Center
Alessandra Cesano, MD, PhD –
ESSA Pharma Inc.
2:10–3:25 p.m. EST

2:10 p.m.

Introduction
(View On-demand)
Sangeeta Goswami, MD, PhD – The University of Texas MD Anderson Cancer Center

2:15 p.m.

Utility of the Circulating Tumor Genome in Informing Clinical Decisions-Immunotherapy and Combinations
(View On-demand)
Priti S. Hegde, PhD – Foundation Medicine

2:33 p.m.

Pronostic and Predictive Value of Tertiary Lymphoid Structures in Human Cancers
(View On-demand)
Catherine Sautes-Fridman, PHD – Centre de Recherche des Cordeliers

2:51 p.m.

no_symbol.png

Host Biomarkers (Microbiome)
Christine Spencer, PhD Parker Institute for Cancer Immunotherapy

3:09 p.m.

(76) Spatial mapping of T cell receptors and transcriptomes in renal cell carcinoma following immune checkpoint inhibitor therapy
(View On-demand)
Bryan Iorgulescu, MD Dana-Farber Cancer Institute

Concurrent Session 110: Microbiome, Metabolism and ER Stress
Location:
East Salons
Co-Chairs:

Laurie H. Glimcher, MD – Dana-Farber Cancer Institute
Jennifer A. Wargo, MD, MMSc – The University of Texas MD Anderson Cancer Center

2:10–3:25 p.m. EST

2:10 p.m

Overview
(View On-demand)

Jennifer A. Wargo, MD, MMSc – The University of Texas MD Anderson Cancer Center

2:15 p.m.  

ER Stress
(View On-demand)

Juan R. Cubillos-Ruiz, PhD – Weill Cornell Medicine

2:30 p.m.

no_symbol.png

Microbiome
Wendy Garrett, MD  – Harvard School of Public Health

2:45 p.m.

Metabolic Impact on Tumor Immunity and Therapy
(View On-demand)

Weiping Zou, MD, PhD – University of Michigan

3:00 p.m. 

(839) Microbiota-specific T follicular helper cells drives tertiary lymphoid structure formation and anti-tumor immunity in colorectal cancer
(View On-demand)
Abigail Overacre-Delgoffe, PhD – University of Pittsburgh

3:05 p.m.

no_symbol.png

(668) Lipid-instructed metabolic rewiring unleash the anti-tumor potential of CD8+ T cells
Teresa Manzo, PhD – IEO

3:10 p.m.

Question and Answer
(View On-demand)

Concurrent Session 111: Intratumoral Therapy at a Crossroads
Location:
202AB
Co-Chairs: 

Nina Bhardwaj, MD, PhD – The Tisch Cancer Institute at the Ichan School of Medicine at Mount Sinai
Adi Diab, MD –
The University of Texas MD Anderson Cancer Center
2:10–3:25 p.m. EST

2:10 p.m.

Introduction
(View On-demand)
Nina Bhardwaj, MD, PhD – The Tisch Cancer Institute at the Ichan School of Medicine at Mount Sinai

2:15 p.m.

State of the Field and Recent Trials
(View On-demand)
Adi Diab, MD – The University of Texas MD Anderson Cancer Center

2:25 p.m.

Standards for Intratumoral Therapies
(View On-demand)
Aurelien Marabelle, MD, PhD – Gustave Roussy

2:35 p.m.

Endpoints for Efficacy
(View On-demand)
Ignacio Melero, MD, PhD FIMA, Clinica Universidad de Navarra

2:45 p.m.

Igniting the Fire: Intratumoral Therapy to Turn on Immune Response to Cancer
(View On-demand)

Antoni Ribas, MD, PhD – University of California Los Angeles

2:55 p.m.

Panel Discussion
(View On-demand)
Aurelien Marabelle, MD, PhD – Gustave Roussy
Ignacio Melero, MD, PhD – FIMA, Clinica Universidad de Navarra
Joshua Brody, MD – Ichan School of Medicine at Mount Sinai
Antoni Ribas, MD, PhD – University of California Los Angeles
Robert Andtbacka, MD, CM, FACS, FRCSC – Seven and Eight Biopharmaceuticals
Stephen Solomon, MD – Memorial Sloan Kettering Cancer Center
Craig L. Slingluff, MD – University of Virginia School of Medicine
Silvia Formenti, MD – Weill Cornell Medicine

Session 112: Debate: Engineered vs. Endogenous T cells
Location:
Hall D
Co-Chairs: 

Alex Marson, MD, PhD – University of California San Francisco
Cassian Yee, MD –
The University of Texas MD Anderson Cancer Center
3:25–4:35 p.m. EST

3:25 p.m.

Endogenous T cells
(View On-demand)
Cassian Yee, MD – The University of Texas MD Anderson Cancer Center

3:40 p.m.

no_symbol.png

Targeting Solid Malignancies with "Public" Neoantigen-Specific T Cells
Christopher A. Klebanoff, MD – Memorial Sloan Kettering Cancer Center

3:55 p.m.

Reprogramming T cell therapies with CRISPR
(View On-demand)
Alexander Marson, MD, PhD – University of California San Francisco

4:10 p.m.

no_symbol.png

Engineered T cells Engineering Next Generation CAR-T Cells for Cancer
Yvonne Chen, PhD – University of California Los Angeles

4:25 p.m.

no_symbol.png

Panel Debate
Yvonne Chen, PhD – University of California Los Angeles
Christopher A. Klebanoff, MD – Memorial Sloan Kettering Cancer Center
Alexander Marson, MD, PhD – University of California San Francisco
Cassian Yee, MD – The University of Texas MD Anderson Cancer Center

4:35–4:50 p.m. EST

Break

Session 113: Debate: Declassification/deconvolution of T cell types
Location:
Hall D
Co-Chairs: 

Ira Mellman, PhD – Genentech, Inc.
Ansuman Satpathy, MD, PhD – Stanford
4:50–6 p.m. EST

4:50 p.m.

Introduction
(View On-demand)
Ansuman Satpathy, PhD Stanford University

4:55 p.m.

Brief Summary – Exhaustion Side
(View On-demand)
E. John Wherry, PhD University of Pennsylvania

5:05 p.m.

no_symbol.png

Brief Summary – Non-Exhausted Side
Andrea Schietinger, PhD Memorial Sloan Kettering Cancer Center

5:15 p.m.

no_symbol.png

Panel Debate
E. John Wherry, PhD University of Pennsylvania
Drew M. Pardoll, MD, PhD Johns Hopkins University
Haydn Kissick, PhD –
Emory University
Andrea Schietinger, PhD Memorial Sloan Kettering Cancer Center

Session 114: Poster Symposium
Location:
Hall D
Co-Chairs:

Diwakar Davar, MD UPMC Hillman Cancer Center
Amanda Lund, PhD NYU Grossman School of Medicine
6–7 p.m. EST

6 p.m.

(30) Blood-based Glycoprotein Signatures in Advanced Non-Small-Cell Lung Carcinoma (NSCLC) Receiving First-Line Immune Checkpoint Blockade
(View On-demand)

Klaus Lindpaintner, MD, MPH InterVenn

6:10 p.m

(748) Targeting vasoactive intestinal peptide receptor signaling in pancreatic ductal adenocarcinoma for enhanced anti-tumor response to checkpoint blockade
(View On-demand)

Sruthi Ravindranathan, PhD, MS Emory University

6:20 p.m.

no_symbol.png

(663) Media based on the metabolic composition of tumor intersitial fluid reveals persistent T cell dysfunction induced through arginine deprivation and exposure to the oncometabolite phosphoethanolamine
Yupeng Wang, BS University of Pittsburgh

6:30 p.m.

no_symbol.png

(683) Type-I-interfereon activates cross-dressed CD11b+ conventional dendritic cells to enhance anti-tumor immuity
Ellen Duong, ScB Koch Institute

6:40 p.m.

(66) Prognostic and predictive value of pre-treatment T-Cell receptors (TCR) repertoire in non-small cell lung cancer (NSCLC) patients with single agent immunotherapy
(View On-demand)

Afaf Abed, MBBS, FRACP Edith Cowan University

6:50 p.m.

Question and Answer
(View On-demand)

7–8:30 p.m. EST

Poster Reception

Location:

Hall E

Saturday, Nov. 13, 2021

Annual Meeting
Walter E. Washington Convention Center

7:15 a.m.–8 p.m. EST

no_symbol.png Indicates that the presentation is not available on-demand.
Click (View On-demand) to view or purchase presentations that are available on-demand.

 


7 a.m.–8:30 p.m. EST

Poster and Exhibit Hall

Location:

Hall E

Session 200: SITC Business Meeting
Location:
Hall D
Chair:

Patrick Hwu, MD  – Moffitt Cancer Center
7:15–7:45 a.m. EST

Organizer Welcome
Location: 
Hall D
Chair:
Padmanee Sharma, MD, PhD – The University of Texas MD Anderson Cancer Center
8–8:05 a.m. EST

Awards Ceremony
8:05–8:20 a.m. EST
Location:
Hall D
Chair:

Leisha A. Emens, MD, PhD – UPMC Hillman Cancer Center

8:05 a.m.

Tara Withington Public Service

8:10 a.m.

Service to JITC

8:15 a.m.

2021 JITC Best Paper

Session 201: Update Session
8:20–9:05 a.m. EST
Location:
Hall D
Chair:

Leisha A. Emens, MD, PhD – UPMC Hillman Cancer Center

8:20 a.m.

Journal for ImmunoTherapy of Cancer (JITC) Update
(View On-demand)
Pedro J. Romero, MD University of Lausanne & University Hospital of Lausanne

8:30 a.m.

National Cancer Institute (NCI) Update
(View On-demand)
Stephanie L. Goff, MD, FACS – National Cancer Institute Surgery Branch

8:45 a.m.

Remembrance of Drs. Martin 'Mac' Cheever and Thomas Waldmann
(View On-demand)
Patrick Hwu, MD – Moffitt Cancer Center
Philip D. Greenberg, MD – Fred Hutchinson Cancer Center
Carol Waldmann, MD

Session 202: Richard V. Smalley Memorial Award and Lectureship
Location:
Hall D
Chair:

Patrick Hwu, MD – Moffitt Cancer Center
9:05–9:55  a.m. EST

9:05 a.m.

Introduction & 2021 Richard V. Smalley Memorial Award and Lectureship Recognition
(View On-demand)
Patrick Hwu, MD – Moffitt Cancer Center

9:10 a.m.

CAR-T Cells for Solid Tumors: Charting a Path Forward
(View On-demand)
Crystal Mackall, MD – Stanford University

9:50 a.m.

Question and Answer
(View On-demand)
Crystal Mackall, MD – Stanford University

9:55 – 10:10 a.m.

Break

Session 203: COVID Immunobiology/Immunology
Location:
Hall D
Co-Chairs: 

Nina Bhardwaj, MD, PhD – The Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai
Kizzmekia Corbett, PhD –
National Institutes of Allergy and Infectious Diseases, NIH
10:10 a.m.–Noon EST

10:10 a.m.

Opening Remarks
(View On-demand)

Kizzmekia Corbett, PhD – National Institutes of Allergy and Infectious Diseases, NIH

10:15 a.m.

Immune Memory to COVID-19 Infection
(View On-demand)

Rafi Ahmed, PhD Emory University

10:37 a.m.

Immune responses to SARS-COV2 vaccination in Multiple Myeloma
(View On-demand)

Samir Parekh, MD – Mount Sinai School of Medicine

10:59 a.m.

T-cell Responses to COVID-19
(View On-demand)
Alesandrao Sette, MD – La Jolla Institute for Immunology

11:21 a.m.

(625) COVID-19 vaccination in patients with renal cancer or melanoma receiving immune checkpoint inhibitors
(View On-demand)

Hannah E. Dzimitrowicz, MD Duke Cancer Center

11:38 a.m.

(626) Dissecting the spatial heterogeneity of SARS-CoV-2-infected tumour microenvironment reveals a lymphocyte-dominant immune response in a HBV-associated HCC patient with COVID-19 history
(View On-demand)

Mai Chan Lau, PhD Institute of Molecular and Cell Biology (IMCB), Agency of Science, Technology and Research (A*STAR)

11:55 a.m.

Closing Remarks
(View On-demand)

Session 204: Late-Breaking Abstract Session
Location:
Hall D
Chair:
Niroshana Anandasabapathy, MD, PhD – Weill Cornell Medicine
Noon–12:30 p.m. EST

Noon

no_symbol.png

(959) Safety and anti-tumor activity of TCR-engineered autologous, PRAME-directed T cells across multiple advanced solid cancers at low doses – clinical update on the ACTengine® IMA203 trial
Martin Wermke – Uniklinikum Dresden

12:15 p.m.

(955) CORE1: Phase 2, Single Arm Study of CG0070 Combined with Pembrolizumab in Patients with Non Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG)
(View On-demand)
Roger Li, MD – Moffitt Cancer Center

12:30–2 p.m. EST

Lunch and Poster Viewing

Location:

Hall E

Concurrent Rapid Oral Abstract Presentation Session 205: Basic Research
Location:
West Salons
Co-Chairs:

Kristin G. Anderson, PhD Fred Hutchinson Cancer Research Center
Olivia Rongze Lu, PhD – University of Texas at Austin, Dell Medical School
12:45–1:45 p.m. EST

12:45 p.m.

(43) Intravital multiphoton imaging of infiltrating CD8 T cell metabolism during immunotherapy in a murine melanoma model
(View On-demand)
Alexa R. Heaton, PhD Morgridge Institute of Research, University of Wisconsin

12:53 p.m.

(658) CD8 T cell activation in cancer is comprised of two distinct phases
(View On-demand)
Nataliya Prokhnevska, BS Emory University

1:01 p.m.

(660) Targeting T cell fates: converting exhaustion to memory to improve immunotherapeutic responses to cancer
(View On-demand)
Nicole E. Scharping, PhD University of California San Diego

1:09 p.m.

Question and Answer
(View On-demand)

1:15 p.m.

no_symbol.png

(936) Stromal remodeling regulates dendritic cell abundance in the tumor microenvironment
Athanasios Papadas, MD, PhD University of California San Diego

1:23 p.m.

(601) Sequencing Immunotherapy Before Lymphatic Ablation Unleashes cDC1-Dependent Antitumor Immunity in HNSCC
(View On-demand)
Robert Saddawi-Konefka, MD, PhD University of California San Diego School of Medicine

1:31 p.m.

(125) Co-opting IL-8 to enhance efficacy of B7H3 CAR T cells against pediatric sarcoma
(View On-demand)
Jessica Lake, MD, MPH University of Colorado Anschutz Medical Campus

1:39 p.m.

Question and Answer
(View On-demand)

Concurrent Rapid Oral Abstract Presentation Session 206: Clinical
Location:
East Salons
Co-Chairs:

Praveen Bommareddy, MS, PhD Replimune Inc.
Chris Langsdorf Thermo Fisher Scientific
12:45–1:45 p.m. EST

12:45 p.m.

(493) First-in-human phase 1/2 trial to evaluate the safety and initial clinical activity of DuoBody®-CD40x4-1BB (GEN1042) in patients with advanced solid tumors
(View On-demand)
Melissa L. Johnson, MD Sarah Cannon Research Institute

12:53 p.m.

(350) Phase 2 trial of a DNA vaccine with pembrolizumab in patients with metastatic, castration-resistant prostate cancer (mCRPC)
(View On-demand)
Douglas G. McNeel, MD, PhD Carbone Cancer Center, University of Wisconsin

1:01 p.m.

(449) Concurrent ibrutinib enhances T cell function in patients with chronic lymphocytic leukemia (CLL) treated with liscabtagene maraleucel (liso-cel), a chimeric antigen receptor (CAR) T cell therapy
(View On-demand)
Jerill Thorpe, MS Bristol Myers Squibb

1:09 p.m.

Question and Answer
(View On-demand)

1:15 p.m.

(374) A Phase IB trial of ziv-afilibercept plus pembrolizumab in patients with advanced solid tumors
(View On-demand)
Kevin Tyan, BA Harvard Medical School

1:23 p.m.

no_symbol.png

(529) Phase 1 study of INCB086550, an oral PD-L1 inhibitor, in immune-checkpoint naive patients with advanced solid tumors
Eric Van Cutsem, MD, PhD University Hospital Gathiusberg Leuven

1:31 p.m.

(490) Clinical benefit through Siglec-15 targeting with NC318 antibody in subjects with Siglec-15 positive advanced solid tumors
(View On-demand)
Elaine Shum, MD New York University Langone Health

1:39 p.m.

Question and Answer
(View On-demand)

Session 207: Presidential Session
Location:
Hall D
Chair: 

Patrick Hwu, MD – Moffitt Cancer Center
2–3:25 p.m. EST

2:00 p.m.

Introduction
(View On-demand)

Patrick Hwu, MD Moffitt Cancer Center

2:05 p.m.

no_symbol.png

(592) ATR-mediated CD47 and PD-L1 upregulation restricts radiotherapy-induced immune priming and abscopal responses in colorectal cancer
Rodney Cheng-En Hsieh, MD The University of Texas MD Anderson Cancer Center

2:20 p.m.

(900) Depleting non-canonical, cell-intrinsic PD-L1 signals induces synthetic lethality to small molecule DNA damage response inhibitors in an immune independent and dependent manner
(View On-demand)

Anand V. Kornepati University of Texas Health Science Center San Antonio

2:35 p.m.

Expert Discussant
(View On-demand)

Sandra Demaria, MD Weill Cornell Medicine

2:45 p.m.

(152) Common trajectories of highly effective anti-CD19 chimeric antigen receptor-modified T cells identified by endogenous T cell receptor lineages
(View On-demand)

Taylor L. Wilson, BS St. Jude Children's Research Hospital

3:00 p.m.

(328) Batf3 dendritic cells and 4-1BB/4-1BB ligand axis are required at the effector phase within tumor microenvironment for anti0PD-L1 efficacy
(View On-demand)

Andrea Ziblat, PhD University of Chicago

3:15 p.m.

Expert Discussant
(View On-demand)

E. John Wherry, PhD University of Pennsylvania

3:25–3:40 p.m. EST

Break

Concurrent Session 208: Locoregional Therapies, Including Radiation, Oncolytic Viruses and Innate Immune Modulators
Location:
West Salons
Co-Chairs: 

James W. Welsh, MD – The University of Texas MD Anderson Cancer Center
Dimitriy Zamarin, MD, PhD –
Memorial Sloan Kettering Cancer Center
3:40–4:55 p.m. EST

3:40 p.m.

Using Low Dose Radiation and Nanoparticles to address PD1 Resistance
(View On-demand)
James W. Welsh, MD – The University of Texas MD Anderson Cancer Center

4 p.m.

no_symbol.png

Modulation of Anti-Tumor Immunity with Oncolytic Viruses
Dimitriy Zamarin, MD, PhD – Memorial Sloan Kettering Cancer Center

4:20 p.m.

no_symbol.png

Modulators of Tumor Antigenicity by Radiation Therapy
Nils Rudqvist, PhD – The University of Texas MD Anderson Cancer Center

4:30 p.m.

(768) Systemic delivery of a tumor-targeted TLR9 agonist conjugate transforms the tumor immune landscape and induces tumor regression in mice
(View On-demand)
Caitlyn Miller, PhD Candidate Stanford University

4:40 p.m.

(758) High-potency synthetic STING agonists rewire the myeloid stroma in the tumor microenvironment to amplify immune checkpoint blockade efficacy in refractory pancreatic ductal adenocarcinoma
(View On-demand)
Akash R. Boda, MS The University of Texas MD Anderson Cancer Center

4:50 p.m.

Questions
(View On-demand)

Concurrent Session 209: Single Cell Approaches to Advancing Understanding of Immunotherapy Resistance
Location:
202AB
Co-Chairs:

Kellie N. Smith, PhD – Johns Hopkins School of Medicine
Daniel K. Wells, PhD –
Parker Institute for Cancer Immunotherapy
3:40–4:55  p.m. EST

3:40 p.m.

Introduction
(View On-demand)
Kellie N. Smith, PhD – Johns Hopkins School of Medicine

3:45 p.m.

Keynote
(View On-demand)
Ansuman Satpathy, MD, PhD Stanford University School of Medicine

4:10 p.m.

Longitudinal Single Cell Genomics Reveals Mechanisms of Resistance to Combination Immune Checkpoint Blockade
(View On-demand)
Alexander Huang, MD University of Pennsylvania

4:20 p.m.

Increased Post-Infusion CD57+ CD19-CAR T Cells in Patients with Durable Remission
(View On-demand)
Zinaida Good, PhD Stanford University

4:30 p.m.

no_symbol.png

Epigenomic Features of Exhausted T-cells During Immunotherapy
Debattama Sen, PhD Massachusetts General

4:40 p.m.

no_symbol.png

(655) Landscape of helper and regulatory CD4+ T cells in melanoma
Giacomo Oliveira, PhD Dana-Farber Cancer Institute

4:50 p.m.

Closing Remarks
(View On-demand)
Daniel K. Wells, PhD – Parker Institute for Cancer Immunotherapy

Concurrent Session 210: Novel Targets, Resistance Mechanisms
Location:
Hall D
Co-Chairs: 

Jason J. Luke, MD, FACP – UPMC
Irving L. Weissman, MD – Stanford University
3:40–4:55 p.m. EST

3:40 p.m.

Targeting Glycobiology as a Therapeutic Approach in Cancer Immunotherapy
(View On-demand)
Carolyn Bertozzi, PhD Stanford University

3:55 p.m.

Normal and Neoplastic Stem Cells
(View On-demand)
Irving L. Weissman, MD – Stanford University

4:10 p.m.

Moving Beyond First Generation STING Agonist Approaches
(View On-demand)
Jason J. Luke, MD, FACP – UPMC Hillman Cancer Center

4:25 p.m.

Flanking Solid Tumors via Immune-Mediated Disruption of Desmoplastic Stroma
(View On-demand)
Ellen Pure, PhD University of Pennsylvania

4:40 p.m.

(261) A functional genetic screen uncovers regulators of intratumoral macrophages function and reveals CD24 as a novel target for cancer immunotherapy by macrophages
(View On-demand)
Amira Barkal, MD, PhD Brigham & Women's Hospital

Concurrent Session 211: Team Science to Catalyze Advancements in Research
Location:
207
Co-Chairs: 

Luis A. Diaz, MD – Memorial Sloan Kettering Cancer Center
Mark Stewart, PhD –
Friends of Cancer Research
3:40–4:55 p.m. EST

3:40 p.m.

no_symbol.png

TMB in immunotherapy: is the hype justified?
Luc Morris, MD Memorial Sloan Kettering Cancer Center

3:55 p.m.

High TMB Fails to Predict Immune Checkpoint Blockade Response in All Cancer Types
(View On-demand)
Daniel J. McGrail, PhD The University of Texas MD Anderson Cancer Center

4:10 p.m.

KN158 TMB Data
(View On-demand)
Aurelien Marabelle, MD, PhD Gustave Roussy

4:25 p.m.

UVB-induced Tumor Heterogeneity Directs Immune Response in Melanoma
(View On-demand)
Yardena Samuels, PhD – Weizmann Institute of Science

4:40 p.m.

no_symbol.png

Panel Discussion
Aurelien Marabelle, MD, PhD Gustave Roussy
Daniel J. McGrail, PhD The University of Texas MD Anderson Cancer Center
Luc Morris, MD Memorial Sloan Kettering Cancer Center
Eric Rubin, MD – Merck
Yardena Samuels, PhD – Weizmann Institute of Science

Concurrent Session 212: Cellular Therapies
Location:
East Salons
Co-Chairs: 

Michel Sadelain, MD, PhD – Memorial Sloan Kettering Cancer Center
Philip D. Greenberg, MD –
Fred Hutchinson Cancer Center
3:40–4:55 p.m. EST

3:40 p.m.

(561) Triple checkpoint blockade, but not anti-PD1 alone, enhances the efficacy of engineered adoptive T cell therapy in advanced ovarian cancer
(View On-demand)
Kristin G. Anderson, PhD Fred Hutchinson Cancer Center

3:55 p.m.

no_symbol.png

(578) CD8-targeting IL-2 drives potent anti-tumor efficacy and promotes action of tumor specific vaccines
Robert D. Schreiber, PhD –  Washington University School of Medicine

4:10 p.m.

(117) FT536 Path to IND: Ubiquitous targeting of solid tumors with an off-the-shelf, first-of-kind MICA/B-specific CAR-iNK cellular immunotherapy
(View On-demand)
Bryan Hancock, PhD Fate Therapeutics

4:25 p.m.

no_symbol.png

(221) CRISPR screen identifies loss of IFNγR signaling and downstream adhesion as a resistance mechanism to CAR T-cell cytotoxicity in solid but not liquid tumors
Rebecca C. Larson, BS Jounce Therapeutics

4:40 p.m.

no_symbol.png

(132) HLA-independent T cell receptors effectively target low abundance antigens
Jorge Mansilla-Soto, PhD Memorial Sloan Kettering Cancer Center

Concurrent Session 213: A Multidisciplinary Approach to Neoadjuvant, Intralesional, and Cell-based Immunotherapy
Location:
204ABC
Co-Chairs: 

Genevieve Boland, MD, PhD Massachusetts General Hospital
Kelly Olino, MD, FACS Yale School of Medicine
3:40–4:55 p.m. EST

3:40 p.m. Neoadjuvant Immunotherapy in Sarcoma
(View On-demand)

Christina Roland, MD The University of Texas MD Anderson Cancer Center
3:55 p.m. Intralesional Treatment in Head and Neck Cancer
(View On-demand)

Sara Pai, MD, PhD Massachusetts General Hospital/Harvard
4:15 p.m. T cell-based Immunotherapy for Metastatic Breast Cancer
(View On-demand)

Stephanie Goff, MD National Cancer Institute
4:30 p.m. (492) Phase 2 efficacy and safety of autologus tumor-infiltrating lymphocyte (TIL) cell therapy in combination with pembrolizumab in immune checkpoint inhibitor-naive patients with advanced cancers
(View On-demand)

David O'Malley –  OSU Medical Center

4:40 p.m. (337) Intratumoral immune therapy for recurrent breast cancer with polyICLC, and tremelimumab combined with systemic duravlumab
(View On-demand)

Craig Slingluff, MD University of Virginia
4:50 p.m.
Closing Remarks
(View On-demand)

4:55–5:10 p.m. EST

Break

Concurrent Session 214: Radiomics & Imaging
Location:
202AB
Co-Chairs: 

Neeta Pandit-Taskar, MD – Memorial Sloan Kettering Cancer Center
Ian A. Wilson, PhD –
ImaginAb Inc.
5:10–6:25 p.m. EST

 5:10 p.m.

CT Radiomics in Immuno-Oncology Clinical Development for Lung Cancer
(View On-demand)
Qin Li, MD, PhD AstraZeneca

 5:35 p.m.

Emerging Technologies to Image  Immune Cell Changes in  Response to Therapy
(View On-demand)
Elisabeth de Vries, MD, PhD University of Groningen

 6:00 p.m.

Cell Labelling Methods to Track Immune Cells
(View On-demand)
Peter Choyke, MD   National Institutes of Health

Concurrent Session 215: Clinical Considerations for Toxicity Management and Survivorship
Location:
207
Co-Chairs: 

Marc S. Ernstoff, MD – National Institute of Health
Mary-Kate Kasler, DNP –
Memorial Sloan Kettering Cancer Center
5:10–6:25 p.m. EST

5:10 p.m.

Clinical Considerations for Immune Checkpoint Inhibitor Toxicity Management and Survivorship
(View On-demand)
Marianne Davies, DNP, AOCNP Yale School of Nursing

5:30 p.m.

Survivorship & Toxicity Management – Physician Perspective
(View On-demand)
Jarushka Naidoo, MBBCH, MHS – Beaumont Hospital Dublin

5:50 p.m.

(234) Distinct efficacy and immunological responses to to αPD-1, ⍺PD-L1 and ⍺PD-L2 immunotherapy in aged versus young hosts
(View On-demand)
Myrna G. Garcia, BS UTHSA

6 p.m.

no_symbol.png

(806) PD-1 blockade affects inflammation and metabolic flexibility to potentially mediate cardiac immune-related adverse events
Steven M. Bronson, DVM Wake Forest School of Medicine

6:10 p.m.

(814) Cutaneous Immune-related Adverse Events are Protective of Mortality in Patients Treated with anti-PD1 and anti-PDL1 therapy in a multi-institutional cohort study
(View On-demand)
Yevgeniy R. Semenov, MD Massachusetts General Hospital, Harvard Medical School

6:20 p.m.

Expert Discussant
(View On-demand)
Igor Puzanov, MD, MSCI, FACP Roswell Park Comprehensive Cancer Center

Concurrent Session 216: Exosomes and Cellular Engineering
Location:
West Salons
Co-Chairs:

Sriram Sathyanarayanan, PhD – Codiak BioScience
Helen E. Heslop, MD –
Baylor College of Medicine
5:10–6:25 p.m. EST

5:10 p.m.

no_symbol.png

Towards Tumor-Specificity: Engineering CAR T cells to Target the Tn-glycopeptidome
Avery D. Posey, PhD –  University of Pennsylvania School of Medicine

5:30 p.m.

no_symbol.png

Next-Generation Approaches
Marcela V. Maus, MD, PhD Massachusetts General Hospital

5:50 p.m.

no_symbol.png

Developing Engineered Exosome Based Therapeutics for Immuno-Oncology
Sriram Sathyanarayanan, PhD – Codiak Biosciences

6:10 p.m.

(130) Engineered natural killer cells reactively block TGIT and CD73 in the GBM microenvironment
(View On-demand)
Kyle B. Lupo, BS Purdue University

Concurrent Session 217: Neoadjuvant Therapies
Location:
East Salons
Co-Chairs: 

Christian U. Blank, MD The Netherlands Cancer Institute
Tina Cascone, MD, PhD – The University of Texas MD Anderson Cancer Center
5:10–6:25 p.m. EST

5:10 p.m.

Monitoring B cells and TLS: Important Insights for Neoadjuvant Clinical Trials
(View On-demand)

Tullia C. Bruno, PhD University of Pittsburgh

5:30 p.m.

Neoadjuvant in Melanoma: The Perfect Model
(View On-demand)

Georgina Long, MBBS, PhD, BSc, FRAC The University of Sydney

5:50 p.m.

Immune Repertoire T cell Overview in Neoadjuvant Immunotherapy
(View On-demand)

Kellie N. Smith, PhD Johns Hopkins School of Medicine

6:10 p.m.

Panel Discussion
(View On-demand)

Tullia C. Bruno, PhD University of Pittsburgh
Georgina Long, MBBS, PhD, BSc, FRAC The University of Sydney
Kellie N. Smith, PhD Johns Hopkins School of Medicine

Concurrent Session 218: Immune Checkpoints – New Indications, Mechanisms, and Controversies
Location:
Hall D
Co-Chairs:

Piers J. Ingram, PhD – Hummingbird Bioscience Pte Ltd
Paolo A. Ascierto, MD –
Istituto Nazionale Tumori IRCCS Fondazione G. Pascale
5:10–6:25 p.m. EST

5:10 p.m.

VISTA: a Promising Target for Cancer Immunotherapy
(View On-demand)

Piers J. Ingram, PhD Hummingbird Bioscience Pte Ltd

5:30 p.m.

Adenosine Pathway as New Possible Target for Immunotherapy
(View On-demand)

John Stagg, PhD CHUM Research Centre

5:50 p.m.

Is Anti-LAG-3 the Next Effective Immunotherapy Treatment? Certainties and Controversies
(View On-demand)

Paolo A. Ascierto, MD – Istituto Nazionale Tumori IRCCS Fondazione G. Pascale

6:10 p.m.

no_symbol.png

(270) Anti-CD47 immunotherapy as a therapeutic strategy for the treatment of breast cancer brain metastasis
Jessica D. Mackert, PhD Wake Forest University

6:30–7 p.m. EST

Award Ceremony

Location:

Hall D

7–8:30 p.m. EST

Poster Reception

Location:

Hall E

8:30–11:30 p.m. EST

The CheckPoints Party

Location:

Liberty Ballroom (Marriott Marquis)

Sunday, Nov. 14, 2021

Annual Meeting
Walter E. Washington Convention Center

8 a.m.–2:20 p.m. EST

no_symbol.png Indicates that the presentation is not available on-demand.
Click (View On-demand) to view or purchase presentations that are available on-demand.

 

 

Organizer Welcome
Location:
Hall D
Chair:
Paolo A. Ascierto, MD – Istituto Nazionale Tumori IRCCS Fondazione G. Pascale
8–8:05 a.m. EST

Medal of Honor Award and Project Lightspeed
8:05–8:30 a.m. EST
Location:
Hall D
Chair:
Patrick Hwu, MD – Moffitt Cancer Center

8:05 a.m.

Introduction
(View On-demand)

Patrick Hwu, MD Moffitt Cancer Center

8:10 a.m.

Project Lightspeed
(View On-demand)

Ugur Sahin, MD BioNTech
Özlem Türeci, MD
BioNTech

Session 300: Novel bispecifics
Location:
Hall D
Co-Chairs:

Ann F. Cheung, PhD – Dragonfly Therapeutics, Inc.
Dimitris Skokos, PhD – Regeneron Pharmaceuticals, Inc.
8:30–10:30 a.m. EST

8:30 a.m.

Human Costimulatory Bispecific Antibodies in Cancer Immunotherapy: Focus in Solid Tumors
(View On-demand)

Dimitris Skokos, PhD – Regeneron Pharmaceuticals, Inc.

8:52 a.m.

From Classical Antibody to Novel Multispecific Biologics: Applications to T and NK cell Engagers
(View On-demand)

Marielle Chiron Cluster, PhD Sanofi

9:15 a.m.

no_symbol.png

Tetravalent Bispecifics: Next Generation Cancer Therapy to Overcome Immune Evasion
Michelle Morrow, PhD – F-Star Therapeutics

9:37 a.m.

Mobilizing the Immune System with Bispecific Antibodies and Engineered Cytokines
(View On-demand)

John R. Desjarlais, PhD – Xencor, Inc.

10 a.m.

Lessons learned and forward-looking perspectives on bi-/multi-specifics
(View On-demand)

Ann F. Cheung, PhD – Dragonfly Therapeutics, Inc.
Marielle Chiron Cluster, PhD Sanofi
John R. Desjarlais, PhD – Xencor, Inc.

Michelle Morrow, PhD – F-Star Therapeutics
Dimitris Skokos, PhD – Regeneron Pharmaceuticals, Inc.

10:30 – 10:45 a.m. EST

Break

Concurrent Session 301: Hot Topic Symposium: RNA Vaccines: from COVID back to Cancer
Location:
Hall D
Co-Chairs:
Ugur Sahin, MD BioNTech SE
Tal Zaks, MD, PhD Moderna
10:45 a.m.–12:15 p.m. EST

10:45 a.m.

no_symbol.png

Robert S. Meehan, MD – Moderna 

11 a.m.

Mustafa Diken, PhD – TRON Institute
(View On-demand)

11:15 a.m.

Catherine J. Wu, MD – Dana-Farber Cancer Institute
(View On-demand)

11:30 a.m.

no_symbol.png

Noam Solomon, PhD – Immunai

11:45 a.m.

Panel Discussion

Concurrent Session 302: Hot Topic Symposium: ODAC and Accelerated Approvals
Location:
Independence Ballroom (Marriott Marquis)
Co-Chairs:
Alessandra Cesano, MD, PhD ESSA Pharma Inc.
Daniel S. Chen, MD, PhD
Leisha A. Emens, MD, PhD UPMC Hillman Cancer Center
10:45 a.m.–12:15 p.m. EST

10:45 a.m.

Introduction
(View On-demand)

Leisha A. Emens, MD, PhD UPMC Hillman Cancer Center

10:50 a.m.

FDA
(View On-demand)

Gautam Mehta, MD – Food and Drug Administration

11:05 a.m.

Clinical
(View On-demand)

David F. McDermott, MD – Beth Israel Deaconess Medical Center

11:20 a.m.

Biostatistics
(View On-demand)

Elizabeth Garrett-Mayer, PhD – American Society of Clinical Oncology

11:35 a.m.

Pharma Regulatory Affairs
(View On-demand)

Scot Ebbinghaus, MD Merck

11:50 a.m.

Panel Discussion
(View On-demand)
Gautam Mehta, MD – Food and Drug Administration
David F. McDermott, MD – Beth Israel Deaconess Medical Center
Elizabeth Garrett-Mayer, PhD – American Society of Clinical Oncology
Scot Ebbinghaus, MD Merck

12:15–12:45 p.m.

Break

Session 303: Coronavirus, Cancer, and Immunotherapy: Navigating Clinical Trials and Treatment
Location:
Hall D
Co-Chairs:

Margaret K. Callahan, MD, PhD – Memorial Sloan Kettering Cancer Center
Samit Hirawat, MD – Bristol Myers Squibb
12:45–2:45 p.m. EST

12:45 p.m.

Introduction
(View On-demand)
Samit Hirawat, MD – Bristol Myers Squibb

12:50 p.m.

Coronavirus, Cancer, and Immunotherapy: Navigating Clinical trials and Treatment - Clinician Perspective
(View On-demand)
Jeffrey Weber, MD, PhD – NYU Langone Medical Center

1:15 p.m.

Perspectives on Virtual Clinical Trials - A new normal post-COVID
(View On-demand)
Kannan Natarajan, PhD – 
Pfizer

1:40 p.m.

FDA Perspective: Cancer Clinical Trials During Covid-19 Pandemic
(View On-demand)
Lorraine Pelosof, MD, PhD – Food and Drug Administration

2:05 p.m.

Impact of COVID on Clinical Trials and their Conduct
(View On-demand)
Kannan Natarajan, PhD – Pfizer
Lorraine Pelosof, MD, PhD – Food and Drug Administration
Jeffrey Weber, MD, PhD – NYU Langone Medical Center

2:45–3 p.m.

Break

Session 304: Phase-Dependent Regulatory Consideration in Manufacturing of Cellular Therapy Products
Location:
Independence Ballroom (Marriott Marquis)
Co-Chairs:
Emily Hopewell, PhD Indiana University
Alessandra Cesano, MD, PhD ESSA Pharma, Inc.
Cecilia Yeung, MD Fred Hutchinson Cancer Research Center
Raj K. Puri, MD, PhD
Food and Drug Administration
3–4:30 p.m. EST

3 p.m.

FDA - Phase-Dependent Regulatory Considerations for Potency Assays of Unmodified and/or Gene-Modified Cell Therapy Products
(View On-demand)

Kimberly Schultz, PhD Food and Drug Administration

3:20 p.m.

Regulatory Considerations for Late-Stage Manufacturing of Cellular and Gene Therapy Products
(View On-demand)

Matthew Klinker, PhD Food and Drug Administration

3:40 p.m.

no_symbol.png

Phase Appropriate CAR-T Product Development
Sugu Patro Kite, A Gilead Company

3:55 p.m.

Transformations of Potency/Manufacturing Throughout Development - Unmodified Agents
(View On-demand)
Robert Pierce, MD – Sensei Therapeutics

4:10 p.m.

no_symbol.png

Panel Discussion
Matthew Klinker, PhD Food and Drug Administration
Sugu Patro Kite, A Gilead Company
Robert Pierce, MD – Sensei Therapeutics
Kimberly Schultz, PhD Food and Drug Administration


Schedule At-a-Glance

Wednesday, Nov. 10
Pre-Conference Programs


World Immunotherapy Council's 4th Young Investigator Symposium

The Evolution of Immunotherapy: An Exploration of Immunity Beyond T cells, CAR T in Solid Tumors and Novel Combinations

Thursday, Nov. 11
Pre-Conference Programs


Primer on Tumor Immunology and Cancer Immunotherapy™


Immuno-Resistance and Sequencing Symposium

Meet-the-Expert Lunch

Grant Writing Workshop

Friday, Nov. 12
Annual Meeting

36th Annual Meeting

Saturday, Nov. 13
Annual Meeting

36th Annual Meeting

Sunday, Nov. 14
Annual Meeting

36th Annual Meeting